Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 known ✓ | O75116 | 4/20 | 1.00 |
| ▸ | PRKCG known ✓ | P05129 | 5/20 | 0.98 |
| ▸ | PRKCZ known ✓ | Q05513 | 5/20 | 0.98 |
| ▸ | PRKCD known ✓ | Q05655 | 5/20 | 0.98 |
| ▸ | PRKD3 known ✓ | O94806 | 4/20 | 0.98 |
| ▸ | PRKCB known ✓ | P05771 | 4/20 | 0.98 |
| ▸ | PRKCA known ✓ | P17252 | 4/20 | 0.98 |
| ▸ | PRKCH known ✓ | P24723 | 4/20 | 0.98 |
| ▸ | PRKCI known ✓ | P41743 | 4/20 | 0.98 |
| ▸ | PRKCE known ✓ | Q02156 | 4/20 | 0.98 |
| ▸ | PRKCQ known ✓ | Q04759 | 4/20 | 0.98 |
| ▸ | PRKD1 known ✓ | Q15139 | 4/20 | 0.98 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.98 |
| ▸ | ROCK1 known ✓ | Q13464 | 1/20 | 0.98 |
| ▸ | FLT3 known ✓ | P36888 | 9/20 | 0.76 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.57 |
| ▸ | PRKACA | P17612 | 6/20 | 1.00 |
| ▸ | PRKACG | P22612 | 4/20 | 1.00 |
| ▸ | PRKACB | P22694 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL905696 | 1.00 | PRKACA (1.00) | PRKACAROCK2PRKACGPRKACBMAPK1 | |
| Hydrochloric Acid SCHEMBL1048974 | 1.00 | PRKACA (1.00) | PRKACAROCK2PRKACGPRKACBMAPK1 | |
| Hydrochloric Acid SCHEMBL29967768 | 1.00 | PRKACA (1.00) | PRKACAROCK2PRKACGPRKACBMAPK1 | |
| Hydrochloric Acid SCHEMBL1048972 | 1.00 | PRKACA (1.00) | PRKACAROCK2PRKACGPRKACBMAPK1 | |
| SCHEMBL29967929 | 0.99 | PRKACA (1.00) | PRKACAROCK2PRKACGPRKACBMAPK1 | |
| SCHEMBL123495 | 0.99 | PRKACA (1.00) | PRKACAROCK2PRKACGPRKACBMAPK1 | |
| SCHEMBL123496 | 0.99 | PRKACA (1.00) | PRKACAROCK2PRKACGPRKACBMAPK1 | |
| Bromide SCHEMBL3347119 | 0.98 | PRKACA (0.98) | PRKACAROCK2PRKACGPRKACBMAPK1 | |
| Bromide SCHEMBL3347113 | 0.98 | PRKACA (0.98) | PRKACAROCK2PRKACGPRKACBMAPK1 | |
| Hydrochloric Acid SCHEMBL9482815 | 0.90 | PRKACA (0.82) | PRKACAROCK2PRKACGPRKACBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION | 2023-09-14 | — | — | US | claimed |
| WO-2023039578-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION (US) | 2023-03-16 | — | — | WO | claimed |
| EP-4395774-B1 | COMBINATION THERAPY WITH A MEK INHIBITOR AND A SRC INHIBITOR FOR THE TREATMENT OF COLORECTAL CANCER | YEDA RES & DEV (IL) | 2025-08-20 | — | — | EP | disclosed |
| US-20250221953-A1 | TRANS-VACCENIC ACID (TVA) AND DERIVATIVES THEREOF IN T CELL-BASED CANCER THERAPIES | THE UNIVERSITY OF CHICAGO | 2025-07-10 | — | — | US | disclosed |
| CN-119072542-A | Maturation-promoting agent having ALK 5-inhibiting activity and CDK 8/19-inhibiting activity | 千纸鹤治疗公司 | 2024-12-03 | — | — | CN | disclosed |
| EP-4395774-A1 | COMBINATION THERAPY WITH A MEK INHIBITOR AND A SRC INHIBITOR FOR THE TREATMENT OF COLORECTAL CANCER | Yeda Research and Development Co. Ltd (IL) | 2024-07-10 | — | — | EP | disclosed |
| US-20240197746-A1 | COMBINATION THERAPY WITH A MEK INHIBITOR AND A SRC INHIBITOR FOR THE TREATMENT OF COLORECTAL CANCER | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-06-20 | — | — | US | disclosed |
| WO-2023192947-A2 | TRANS-VACCENIC ACID (TVA) AND DERIVATIVES THEREOF IN T CELL-BASED CANCER THERAPIES | THE UNIVERSITY OF CHICAGO (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION | 2023-09-14 | — | — | US | disclosed |
| WO-2023039578-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION (US) | 2023-03-16 | — | — | WO | disclosed |
| WO-2023031925-A1 | COMBINATION THERAPY WITH A MEK INHIBITOR AND A SRC INHIBITOR FOR THE TREATMENT OF COLORECTAL CANCER | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-03-09 | — | — | WO | disclosed |
| WO-2022185742-A1 | PROPHYLACTIC OR THERAPEUTIC COMPOSITION FOR DISSEMINATED INTRAVASCULAR COAGULATION SYNDROME | 学校法人埼玉医科大学 | 2022-09-09 | — | — | WO | disclosed |
| US-20220168325-A1 | METHODS TO PROMOTE CEREBRAL BLOOD FLOW IN THE BRAIN | THE UNIVERSITY OF VERMONT | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250221953-A1 | TRANS-VACCENIC ACID (TVA) AND DERIVATIVES THEREOF IN T CELL-BASED CANCER THERAPIES | GPR65, GPR52, GPR84 | ROCK2 3821/4885PRKCG 1159/4885PRKCZ 1600/4885 |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | TP53, CD4, MCL1 | ROCK2 1445/4885PRKCG 1138/4885PRKCZ 1911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.